Plain-English translation of NCT02185443 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing stereotactic body radiation therapy (SBRT) — a highly focused, intensive form of radiation — to treat cancer that has spread to the liver in patients with colorectal cancer, anal canal cancer, or gastrointestinal neuroendocrine tumors. Unlike traditional radiation, SBRT delivers very high doses of radiation precisely to tumors in just a few sessions, which may help patients whose liver tumors cannot be safely removed by surgery. The goal is to see whether this treatment can control or eliminate these tumors and improve outcomes.
Many patients with liver metastases (cancer that has spread from another organ to the liver) cannot undergo surgery because the tumors are in difficult locations or the patient's health makes surgery too risky. This trial exists to evaluate whether this focused radiation approach can offer these patients a potentially curative treatment option when surgery is not possible.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive stereotactic body radiation therapy delivered in a few carefully planned sessions over a short period. Your doctors will use imaging scans to map exactly where your liver tumors are and aim the radiation beams with precision. You will need to stop chemotherapy at least 2 weeks before starting treatment and avoid it during radiation. The research team will monitor you closely with follow-up visits and scans to track how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Brazil